華帝股份(002035.SZ):近三年來在研發的投入比例保持在4%-5%
格隆匯6月28日丨華帝股份(002035.SZ)近期在接待機構調研時表示,公司擁有完善的研發體系和較強的自主研發能力,同時堅持以研發支撐產品創新,以產品創新推動品牌升級,用品牌升級助力企業高質量可持續發展。因此,公司非常注重產品的研發創新,並擁有“國家級工業設計中心”、“國家認定企業技術中心”等國家級創新平台,近三年來在研發的投入比例保持在4%-5%。截止2022年底,公司擁有4124項國家級專利技術,位居行業前列,近幾年先後為廚電行業持續輸出各種極富創意性和顛覆性的設計成果如“蓮花淨燃技術”、“飛碟懸浮設計”、“伸縮煙槍近攏吸”等,為行業的產品創新提供智慧源泉。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.